{
  "drug_name": "Spiramycin",
  "url": "https://wikem.org/wiki/Spiramycin",
  "scraped_at": "2026-01-10T08:02:29.585107",
  "sections": {
    "Administration": {
      "text": "Type:\nmacrolide\nantibiotic\nDosage Forms: 250, 500\nRoutes of Administration: PO, IV\nCommon Trade Names: Rovamycine",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "macrolide",
          "url": "https://wikem.org/wiki/Macrolide"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "1-2g PO BID OR 500-1000mg PO TID. May increase to 2-2.5g BID for severe infections\nToxoplasmosis\nin pregnant women:\n1st trimester: 3g PO daily in 3-4 divided doses\n2nd/3rd trimesters: 25-50mg\npyrimethamine\nPO daily AND 2-3g\nsulfadiazine\ndaily AND folinic acid 5mg daily for 3 weeks, alternating with 1g PO spiramycin TID for 3 weeks",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Toxoplasmosis",
          "url": "https://wikem.org/wiki/Toxoplasmosis"
        },
        {
          "text": "pyrimethamine",
          "url": "https://wikem.org/wiki/Pyrimethamine"
        },
        {
          "text": "sulfadiazine",
          "url": "https://wikem.org/wiki/Sulfadiazine"
        }
      ]
    },
    "Pediatric_Dosing": {
      "text": ">20kg: 25mg/kg PO BID or 16.7mg/kg PO TID\nSubclinical congenital toxoplasmosis: 0.5-1mg/kg PO daily\npyrimethamine\nAND 50-100mg/kg PO daily\nsulfadiazine\nx 4 weeks, alternating with 50-100mg/kg spiramycin x 6 weeks, alternating courses for 1 year\nOvert congenital toxoplasmosis: 0.5mg/kg PO\npyrimethamine\ndaily AND 50-100mg/kg\nsulfadiazine\nPO daily AND 5mg folinic acid q3d for 6 months, alternating with 50-100mg/kg spiramycin AND pyrimethamine AND sulfadiazine for 4 weeks. Repeat dosing courses x 18mo",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "pyrimethamine",
          "url": "https://wikem.org/wiki/Pyrimethamine"
        },
        {
          "text": "sulfadiazine",
          "url": "https://wikem.org/wiki/Sulfadiazine"
        },
        {
          "text": "pyrimethamine",
          "url": "https://wikem.org/wiki/Pyrimethamine"
        },
        {
          "text": "sulfadiazine",
          "url": "https://wikem.org/wiki/Sulfadiazine"
        }
      ]
    },
    "Special_Populations": {
      "text": "",
      "subsections": {
        "Pregnancy_Rating": {
          "text": "Category B, Safe in pregnancy\n[1]",
          "tables": []
        },
        "Lactation_risk": {
          "text": "Distributed in breast milk",
          "tables": []
        },
        "Renal_Dosing": {
          "text": "Adult: n/a\nPediatric: n/a",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Caution in hepatic impairment",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pregnancy_Rating": {
      "text": "Category B, Safe in pregnancy\n[1]",
      "subsections": {
        "Lactation_risk": {
          "text": "Distributed in breast milk",
          "tables": []
        },
        "Renal_Dosing": {
          "text": "Adult: n/a\nPediatric: n/a",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Caution in hepatic impairment",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Lactation_risk": {
      "text": "Distributed in breast milk",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult: n/a\nPediatric: n/a",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Caution in hepatic impairment",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Renal_Dosing": {
      "text": "Adult: n/a\nPediatric: n/a",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "Caution in hepatic impairment",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "Caution in hepatic impairment",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "Cardiac toxicity, specifically QT prolongation\nThrombocytopenia\nCholestatic hepatitis\nGI toxicity, specifically acute colitis, C. diff colitis, or other intestinal injury\nUlcerated esophagitis\nWorsening hepatic impairment in patients with pre-existing liver disease",
          "tables": []
        },
        "Common": {
          "text": "Injection site pain\nNausea/vomiting, diarrhea, abdominal pain",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "Cardiac toxicity, specifically QT prolongation\nThrombocytopenia\nCholestatic hepatitis\nGI toxicity, specifically acute colitis, C. diff colitis, or other intestinal injury\nUlcerated esophagitis\nWorsening hepatic impairment in patients with pre-existing liver disease",
      "subsections": {
        "Common": {
          "text": "Injection site pain\nNausea/vomiting, diarrhea, abdominal pain",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "Injection site pain\nNausea/vomiting, diarrhea, abdominal pain",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 4.5-13.5h (increases with increasing age)\nMetabolism: Hepatic\nExcretion: Fecal (predominant), renal",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "Reversibly binds to the 50 S subunit of bacterial ribosomes, resulting in blockage of the transpeptidation or translocation reactions, inhibiting protein synthesis and subsequent cell growth\n[2]",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Comments": {
      "text": "Not approved in US for standard use, though exceptions can be made to treat toxoplasmosis in pregnant women\n[3]",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Toxoplasmosis\nMacrolide",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Toxoplasmosis",
          "url": "https://wikem.org/wiki/Toxoplasmosis"
        },
        {
          "text": "Macrolide",
          "url": "https://wikem.org/wiki/Macrolide"
        }
      ]
    }
  }
}